Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
Bharat Immunological
|
Zenith Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
21.53 % | -29.83 % | 19.81 % |
|
5yr average Equity Multiplier
|
-0.87 | 3.08 | 3.92 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.61 | 1.08 |
|
5yr Avg Net Profit Margin
|
0.0 | -18.38 % | 5.08 % |
|
Price to Book
|
3.08 | 1.02 | 1.14 |
|
P/E
|
18.62 | 0.0 | 11.09 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 206.63 Days | -5.9 Days |
|
Inventory Days
|
0.0 | 125.06 Days | 59.46 Days |
|
Days Receivable
|
0.0 | 61.4 Days | 153.74 Days |
|
Days Payable
|
0.0 | 117.81 Days | 283.33 Days |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | -2.32 | 3.87 |
|
5yr Avg ROCE
|
21.53 % | -44.64 % | 26.61 % |
|
5yr Avg Operating Profit Margin
|
0.0 | -18.7 % | 9.63 % |
|
5 yr average Debt to Equity
|
-1.45 | 0.71 | 1.03 |
|
5yr CAGR Net Profit
|
43.36 % | 23.51 % | 17.92 % |
|
5yr Average Return on Assets
|
-21.34 % | -10.1 % | 5.28 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 59.25 % | 69.98 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
Bharat Immunological
|
Zenith Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|